Condition: Primary Aldosteronism · Cognitive Dysfunction · Mild Cognitive Impairment (MCI) · Sponsor: Xinjiang Medical University
The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are: 1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.
This description comes directly from the study's public registry record.
Xiang Xie, PhD · +86-991-4366892 · xiangxie999@sina.com
Kaige Feng · +86-17828098050 · fengkaigedoc@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Chengdu Medical College | Chengdu, Sichuan, China | Recruiting |
| The First Affiliated Hospital of Xinjiang Medical University | Ürümqi, Xinjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07304674